Pharmaceutical News

RSS

Cambridge Consultants help Clinigen Group to breathe new life into old drugs

Innovative product development and technology consultancy firm Cambridge Consultants has collaborated with Clinigen Group to create a new way of identifying fresh market applications for drugs nearing the end of their product lifecycle.

From Clinigen Group 24 Jul 2013

Baylor Research Institute, Novartis sign license agreement for canakinumab

Baylor Research Institute, the research arm of Baylor Health Care System, announced that it has signed an agreement with Novartis to non-exclusively license Baylor's patents pertaining to the treatment of Systemic Onset Juvenile Idiopathic Arthritis using interleukin-1 beta antagonists.

24 Jul 2013

3-D hydrogel approach to study aggressive and deadly forms of brain cancer

Human glioblastoma multiforme, one of the most common, aggressive and deadly forms of brain cancer, is notoriously difficult to study. Scientists have traditionally studied cancer cells in petri dishes, which have none of the properties of the brain tissues in which these cancers grow, or in expensive animal models.

24 Jul 2013

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

The first large non-commercial clinical study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS), shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

24 Jul 2013

NIH awards $2.35M grant to BUSM researcher to study the development of gonococcal vaccine

Lee Wetzler, MD, an attending physician in the department of infectious diseases at Boston Medical Center and associate program director for research in the section of infectious diseases at Boston University School of Medicine (BUSM), was awarded a four-year, $2.35 million grant from the National Institutes of Health (NIH) to study the development of a gonococcal vaccine.

24 Jul 2013

FDA takes action to remove illegal diabetes products from market

The U.S. Food and Drug Administration is taking action to remove from the market illegal products, including some labeled as dietary supplements, that claim to mitigate, treat, cure or prevent diabetes and related complications.

24 Jul 2013

First Edition: July 23, 2013

Today's headlines include reports that the White House is enlisting celebrities to aid efforts to enroll young people in the health insurance plans that will kick in this fall as a result of the health law.

23 Jul 2013

Discovery may help explain how anti-inflammatory steroid drugs work

A gene long presumed dead comes to life under the full moon of inflammation, Stanford University School of Medicine scientists have found.

23 Jul 2013

Federal judge grants Hobby Lobby a temporary injunction against health law's birth control coverage requirement

A federal judge has temporarily exempted Hobby Lobby Stores Inc from a requirement in the 2010 healthcare law that it offer workers insurance coverage for birth control, which the retailer said violated its religious beliefs. The preliminary injunction issued by U.S. District Judge Joe Heaton in Oklahoma City, where Hobby Lobby is based, covers the arts and crafts chain and its affiliated Mardel Christian bookstore chain (Stempel, 7/19).

23 Jul 2013

Findings show oxytocin strengthens bad memories and increases fear, anxiety

It turns out the love hormone oxytocin is two-faced. Oxytocin has long been known as the warm, fuzzy hormone that promotes feelings of love, social bonding and well-being. It's even being tested as an anti-anxiety drug. But new Northwestern Medicine- research shows oxytocin also can cause emotional pain, an entirely new, darker identity for the hormone.

23 Jul 2013

Improving vaccination rates in boys plays a crucial role against HPV infection

Improving vaccination rates against the human papillomavirus (HPV) in boys is key to protecting both men and women, says new research from University of Toronto Professor Peter A. Newman from the Factor-Inwentash Faculty of Social Work.

23 Jul 2013

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a global license agreement with Azure Biotech for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health.

22 Jul 2013

GW Pharmaceuticals to expand marketing authorization for Sativex to France

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has submitted an application under the European Mutual Recognition Procedure seeking to expand the marketing authorization for Sativex into France for the treatment of spasticity due to Multiple Sclerosis.

22 Jul 2013

Moberg Pharma granted exclusive rights to market Kerasal Nail in China

Moberg Pharma AB today announced that Menarini Asia-Pacific, a member of the Menarini Group - a top 40 global pharmaceutical company - has been granted the exclusive rights to market and sell Kerasal Nail in China. The companies now intend to seek marketing authorization for the product in the Chinese market.

22 Jul 2013

Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.

22 Jul 2013

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

An investigation undertaken by Novozymes Biopharma DK has shown that when the corticosteroid dexamethasone is formulated in a cross-linked Hyaluronic acid (HA) hydrogel, the drug’s in vitro release time increases from under 10 minutes to approximately 15 hours. In addition, the in vivo half-life of dexamethasone is shown to plateau with stable dexamethasone concentration up to four hours after injection.

22 Jul 2013

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.

20 Jul 2013

CETSA helps scientists determine effectiveness of drugs in the body

The search for new drugs, including those for cancer, is set to speed up thanks to a new research technique invented by scientists at the Nanyang Technological University.

20 Jul 2013

Researchers demonstrate that 2-drug combination can eliminate cancer

New research conducted by Harvard scientists is laying out a roadmap to one of the holy grails of modern medicine - a cure for cancer.

20 Jul 2013

Kidney patients who take calcium to lower phosphorous levels at higher risk of death: Study

Kidney patients who take calcium supplements to lower their phosphorous levels may be at a 22 per cent higher risk of death than those who take other non-calcium based treatments, according to a new study by Women's College Hospital's Dr. Sophie Jamal.

20 Jul 2013

Pharmaceutical News

Cambridge Consultants help Clinigen Group to breathe new life into old drugs

Baylor Research Institute, Novartis sign license agreement for canakinumab

3-D hydrogel approach to study aggressive and deadly forms of brain cancer

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

NIH awards $2.35M grant to BUSM researcher to study the development of gonococcal vaccine

FDA takes action to remove illegal diabetes products from market

First Edition: July 23, 2013

Discovery may help explain how anti-inflammatory steroid drugs work

Federal judge grants Hobby Lobby a temporary injunction against health law's birth control coverage requirement

Findings show oxytocin strengthens bad memories and increases fear, anxiety

Improving vaccination rates in boys plays a crucial role against HPV infection

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

GW Pharmaceuticals to expand marketing authorization for Sativex to France

Moberg Pharma granted exclusive rights to market Kerasal Nail in China

Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

CETSA helps scientists determine effectiveness of drugs in the body

Researchers demonstrate that 2-drug combination can eliminate cancer

Kidney patients who take calcium to lower phosphorous levels at higher risk of death: Study

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News